Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Language
  • +91 11 4925 6000
  • Request information
  • +91 11 4925 6000
  • Part of brands: |
IndiaIndia
  • Part of brands: |
  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
Genomics Precision Diagnostic > Neurology Precision Panel > Amyotrophic Lateral Sclerosis Precision Panel

Amyotrophic Lateral Sclerosis Precision Panel

Amyotrophic Lateral Sclerosis (ALS) is the most common degenerative disease of the motor neuron system. It is characterized by the progressive loss of motor neurons in the brain and spinal cord, leading to paralysis. 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Amyotrophic Lateral Sclerosis (ALS) is the most common degenerative disease of the motor neuron system. It is characterized by the progressive loss of motor neurons in the brain and spinal cord, leading to paralysis. It begins insidiously with focal weakness but spreads ceaselessly to involve most muscles, including the diaphragm. The diagnosis of ALS rests on a history of painless progressive weakness coupled with examination findings of upper and lower motor dysfunction. Typically, death is due to respiratory paralysis and it occurs within 3 to 5 years of diagnosis. Many different genes and pathophysiological processes contribute to the disease, more so, there are two types of ALS differentiated by genetics: familial and sporadic. Although ALS is incurable and fatal, with median survival of 3 years, early treatment can lengthen and substantially increase quality of life for patients.  
  • The Igenomix Amyotrophic Lateral Sclerosis Precision Panel can serve as an accurate and directed diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. 

Indication

  • The Igenomix Amyotrophic Lateral Sclerosis Precision Panel is indicated in patients with a clinical suspicion or diagnosis presenting with the following manifestations: 
    • Reduced finger dexterity and cramping 
    • Tripping, stumbling or awkwardness when running 
    • Wrist drop and foot drop
    • Slurred speech and hoarseness 
    • Depression 
    • Impaired executive function  
    • Aspiration or choking 
    • Muscle atrophy 
    • Spasticity 
    • Muscle cramps 
    • Voice changes 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular diagnosis for an accurate clinical diagnosis of a symptomatic patient.    
  • Early initiation of treatment with a multidisciplinary team in the form of medical care with riluzole, enteral nutrition, non-invasive ventilation and preventive measures of complications.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation.  

Genes & Diseases

Methodology

References

See scientific referrals

Miller, R., Jackson, C., Kasarskis, E., England, J., Forshew, D., & Johnston, W. et al. (2009). Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 73(15), 1218-1226. doi: 10.1212/wnl.0b013e3181bc0141 

van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & van den Berg, L. H. (2017). Amyotrophic lateral sclerosis. Lancet (London, England), 390(10107), 2084–2098. https://doi.org/10.1016/S0140-6736(17)31287-4 

Hulisz D. (2018). Amyotrophic lateral sclerosis: disease state overview. The American journal of managed care, 24(15 Suppl), S320–S326. 

Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic Lateral Sclerosis. The New England journal of medicine, 377(2), 162–172. https://doi.org/10.1056/NEJMra1603471 

Tsai, M. J., Hsu, C. Y., & Sheu, C. C. (2017). Amyotrophic Lateral Sclerosis. The New England journal of medicine, 377(16), 1602. https://doi.org/10.1056/NEJMc1710379 

Andersen P. M. (2004). The genetics of amyotrophic lateral sclerosis (ALS). Supplements to Clinical neurophysiology, 57, 211–227. https://doi.org/10.1016/s1567-424x(09)70359-9 

Oskarsson, B., Gendron, T. F., & Staff, N. P. (2018). Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clinic proceedings, 93(11), 1617–1628. https://doi.org/10.1016/j.mayocp.2018.04.007 

Owens B. (2017). Amyotrophic lateral sclerosis. Nature, 550(7676), S105. https://doi.org/10.1038/550S105a 

descargar

Detail description

Download



IGENOMIX_PartOfVitrolifeGroup_black

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

OUR SERVICES

Genetic solutions
Learn about genetics
How to send a sample

ABOUT US

About Igenomix
Contact
Quality
Work with us

FOLLOW IGENOMIX

Blog: Path to fertility

  +91 11 4925 6000
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Language

[2024] © Igenomix Privacy policy Quality policy Legal note Cookies policy




  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
  • Language
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT